Skip to main content

Advertisement

SpringerLink
Log in

Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

The hepatitis C virus (HCV) NS5B protein is an RNA-dependent RNA polymerase that is required for viral genome replication and constitutes the most important target region for drugs being developed as direct-acting antivirals (DAAs) against HCV genotype 1. However, the extreme genetic variability leading to drug resistance mutations and genetic barriers has dramatically compromised the effectiveness of DAA therapy. The purpose of this study was to analyze the genetic variability of NS5B polymerase in HCV patients from different provinces of China to identify the impact of these resistance sites on genetic barriers. We analyzed 3489 NS5B sequences of HCV strains circulating in different regions of China, obtained from the GenBank database, 153 of which were from three cities in Sichuan Province (Yibin, Zigong and Zhangzhou). Sequence alignment was conducted using MEGA 6.0, the genetic information was translated into amino acids, and the percentage of polymorphic amino acid sites was calculated. The Vijver method was used to evaluate the occurrence of genetic barriers in HCV NS5B sequences. Blood samples were collected from 153 HCV patients from Sichuan for NS5B sequence analysis using real-time PCR and the Sanger method. Of the 17 antiviral drug resistance sites summarized from the published literature, nine were found in Chinese NS5B sequences, and C316Y was identified as the dominant mutation. Analysis of genetic barriers revealed that the probability of mutation to a drug-resistance-associated amino acid, in response to selective pressure from antiviral drugs was 100% at site 96 and 99.7% at site 282. Our study is the first to analyze the drug resistance sites and to evaluate genetic barriers in NS5B sequences that could affect the responsiveness of Chinese HCV patients to DAA therapy. The results provide a valuable basis for drug development and introduction of foreign-origin antiviral drugs in China that targeting the HCV NS5B region.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1):77–87

    Article  Google Scholar 

  2. Calvaruso V, Petta S, Craxì A (2018) Is global elimination of HCV realistic? Liver Int 38:40–46

    Article  Google Scholar 

  3. Zaltron S, Spinetti A, Biasi L et al (2012) Chronic HCV infections: epidemiological and clinical relevance. BMC Infect Dis 12(suppl2):S2

    Article  Google Scholar 

  4. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10(5):659–672

  5. Geller R, Estada Ú, Peris JB, Andreu I, Bou JV, Garijo R, Sanjuán R (2016) Highly heterogeneous mutation rates in the hepatitis C virus genome. Nat Microbiol 1(7):1–7

    Article  Google Scholar 

  6. Lu L, Nakano T, He Y et al (2005) Hepatits C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 75:538–549

    Article  CAS  Google Scholar 

  7. Nie B, Zhang G, Guo Y et al (2015) Phylogenetic analysis of HCV subgenotypes in patients from Sichuan province in China based on the NS5B region. Int J Mol Med 36(4):1028–1034

    Article  CAS  Google Scholar 

  8. Cai Q, Zhao Z, Liu Y et al (2013) Comparison of three different HCV genotyping methods: core, NS5B sequence analysis and line probe assay. Int J Mol Med 31:347–352

    Article  CAS  Google Scholar 

  9. Choi JW, Lee JS, Paik WH et al (2016) Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol 22:168–171

    Article  Google Scholar 

  10. Zeuzem S, Berg T, Moeller B et al (2009) Expert opinion on the treatment of patients with chronic hepatits C. J Viral Hepat 16:75–90

    Article  CAS  Google Scholar 

  11. Paparin JL, Amador A, Badaroux E, Bot S, Caillet C, Convard T et al (2017) Discovery of benzophosphadiazine drug candidate IDX375: A novel hepatitis C allosteric NS5B RdRp inhibitor. Bioorgan Med Chem Lett 27(11):2634–2640

    Article  CAS  Google Scholar 

  12. Soriano V, Vispo E, Poveda E et al (2011) Directly acting antivirals against hepatits C virus. J Antimicrob Chemother 66:1673–1686

    Article  CAS  Google Scholar 

  13. Poveda E, Wyles DL, Mena A et al (2014) Update on hepatits C virus resistance to direct-acting antiviral agents. Antiviral Res 108:181–191

    Article  CAS  Google Scholar 

  14. Bruno R, Cima S, Maiocchi L et al (2011) Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C. Dig Liver Dis 43:337–344

    Article  CAS  Google Scholar 

  15. Kliemann DA, Tovo CV, Da Veiga ABG, Machado AL, West J (2016) Genetic barrier to direct acting antivirals in HCV sequences deposited in the European databank. PloS One 11(8):e0159924

    Article  Google Scholar 

  16. Alves R, Queiroz AT, Pessoa MG et al (2013) The presence of resistance mutations to protease and polymerase inhibitors in hepatits C virus sequences from the Los Alamos databank. J Viral Hepat 20:414–421

    Article  CAS  Google Scholar 

  17. Van de Vijver DA, Wensing AM, Angarano G et al (2006) The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 41:352–360

    Article  Google Scholar 

  18. Pawlotsky JM, Chevaiez S, McHutchison JG (2007) The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132:1979–1998

    Article  CAS  Google Scholar 

  19. Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatits C virus. Hepatology 53:1742–1751

    Article  CAS  Google Scholar 

  20. Kiser JJ, Burton JR, Everson GT (2013) Drug-drug interactions during antiviral therapy for chronic hepatits C. Nat Rev Gastroenterol Hepatol 10:596–606

    Article  CAS  Google Scholar 

  21. Cooper C, Lawitz EJ, Ghali P et al (2009) Evaluation of VCH-759 monotherapy in hepatits C infection. J Hepatol 51:39–46

    Article  CAS  Google Scholar 

  22. Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138(2):447–462

    Article  CAS  Google Scholar 

  23. Barreca ML, Iraci N, Manfroni G et al (2011) Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. Future Med Chem 3:1027–1055

    Article  CAS  Google Scholar 

  24. Pirakitikulr N, Kohlway A, Lindenbach BD et al (2016) The coding region of the HCV genome contains a network of regulatory RNA structures. Mol Cell 62:111–120

    Article  CAS  Google Scholar 

  25. McPhee F, Hernandez D, Yu F et al (2013) Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasivr and asunaprevir. Hepatology 58:902–911

    Article  CAS  Google Scholar 

  26. Troke PJ, Lewis M, Simpson P et al (2012) Characterization of resistance to the non-nucleoside NS5B inhibitor filibuvir in hepatitis C virus infected patients. Antimicrob Agents Chemother 56:1331–1341

    Article  CAS  Google Scholar 

  27. Jiao P, Xue W, Shen Y et al (2014) Understanding the drug resistance mechanism of hepatitis C virus NS5B to PF-00868554 due to mutations of the 423 site: a computational study. Mol Biosyst 10:767–777

    Article  CAS  Google Scholar 

  28. Hsu CS (2013) Sofosbuvir for previously untreated chronic hepatits C infection. N Engl J Med 369:678

    Article  CAS  Google Scholar 

  29. Keating GM (2014) Sofosbuvir: a review of its use in patients with chronic hepatits C. Drugs 74:1127–1146

    Article  CAS  Google Scholar 

  30. Lam AM, Espiritu C, Bansal S, Steuer HMM, Niu C, Zennou V et al (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56(6):3359–3368

    Article  CAS  Google Scholar 

  31. Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Najera I (2014) In vivo emer-gence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibi-tors mericitabine and sofosbuvir. J Infect Dis 209:668–675

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The present study was supported by the Science and Technology Bureau of Yibin City (no. 2015 SF 027).

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, The Second People’s Hospital of Yibin, Yibin, 644000, Sichuan, People’s Republic of China

    Bin Nie & Sunguang Yun

  2. Department of Clinical Laboratory, Affiliated TCM Hospital of Southwest Medical University, Luzhou, 646000, People’s Republic of China

    Yongcan Guo

  3. Department of Clinical Laboratory, The First Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China

    Kaijiong Zhang & Jinbo Liu

Authors
  1. Bin Nie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yongcan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaijiong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinbo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sunguang Yun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design of the research, Bin Nie, and Kaijiong Zhang; acquisition and analysis of data, Kaijiong Zhang and Jinbo Liu; obtaining funding, Sunguang Yun; drafting the manuscript, Bin Nie; revision of manuscript, Bin Nie and Sunguang Yun. All authors reviewed the manuscript before submission and approved the final manuscript.

Corresponding author

Correspondence to Sunguang Yun.

Ethics declarations

Conflict of interest

The authors declare no competing interest pertaining to the publication of this paper.

Ethical statement

All procedures in the present study, which involves human participants, were in strict accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments. Written consent was obtained from all of the subjects.

Additional information

Handling Editor: Zhongjie Shi.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 28 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nie, B., Guo, Y., Zhang, K. et al. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China. Arch Virol 165, 2013–2020 (2020). https://doi.org/10.1007/s00705-020-04713-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-020-04713-4

Search

Navigation